National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 370602

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 12/8/2009

VAERS ID: 370602
VAERS Form:
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / - LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 9/14/2017

VAERS ID: 370602 Before After
VAERS Form:(blank) 1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / - UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 2/14/2018

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 6/14/2018

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 8/14/2018

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 9/14/2018

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 10/14/2018

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 12/24/2020

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 12/30/2020

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 5/7/2021

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.


Changed on 5/21/2021

VAERS ID: 370602 Before After
VAERS Form:1
Age:
Sex:Male
Location:Foreign
Vaccinated:2009-01-09
Onset:0000-00-00
Submitted:2009-11-30
Entered:2009-11-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK LA / IM

Administered by: Other      Purchased by: Other
Symptoms: Premature baby, Drug exposure during pregnancy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications: Folic acid
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0563470B

Write-up: This prospective pregnancy case was reported by a nurse practitioner and described the occurrence of premature birth in male neonate exposed to CERVARIX transplacentally when his mother was being vaccinated with CERVARIX. The neonate was also exposed to Folic acid transplacentally, which the mother took concurrently. On 09 January 2009, the 17-year-old mother of the patient received a dose of CERVARIX (1 injection, intramuscular, left deltoid). The mother''s last menstrual period was on 21 December 2008 and estimated date of delivery was on 27 September 2009. The neonate was exposed to CERVARIX during the first trimester. On 21 August 2009, at 34 weeks gestation, the neonate was delivered by normal vaginal delivery and weighed 2.1 kg (head circumference 32 cm). The neonate was born pre-term at 34 weeks gestation and experienced a premature birth. No birth defects were noted. It was reported that "there was no details from the hospital regarding treatment following delivery" and that the neonate was in SCBU". The neonate was hospitalised. At the time of reporting the baby was "12 weeks old and healthy with no obvious problems". The reporting nurse practitioner did not provide a causal relationship between the event and the mother''s treatment with CERVARIX. Please see report B0563470A for details regarding the mother case.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=370602&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166